Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis

Jennifer A. Kanakry; Yvette L. Kasamon; Javier Bolaños-Meade; Ivan M. Borrello; Robert A. Brodsky; Ephraim J. Fuchs; Nilanjan Ghosh; Douglas E. Gladstone; Christopher D. Gocke; Carol Ann Huff; Christopher G. Kanakry; Leo Luznik; William Matsui; Huzefa J. Mogri; Lode J. Swinnen; Heather J. Symons; Richard J. Jones; Richard F. Ambinder

doi:10.1016/j.bbmt.2013.07.013

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis

Jennifer A. Kanakry, Yvette L. Kasamon, Javier Bolaños-Meade, Ivan M. Borrello, Robert A. Brodsky, Ephraim J. Fuchs, Nilanjan Ghosh, Douglas E. Gladstone, Christopher D. Gocke, Carol Ann Huff, Christopher G. Kanakry, Leo Luznik, William Matsui, Huzefa J. Mogri, Lode J. Swinnen, Heather J. Symons, Richard J. Jones, Richard F. Ambinder

School of Medicine

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.

Original language	English (US)
Pages (from-to)	1514-1517
Number of pages	4
Journal	Biology of Blood and Marrow Transplantation
Volume	19
Issue number	10
DOIs	https://doi.org/10.1016/j.bbmt.2013.07.013
State	Published - Oct 2013

Keywords

Allogeneic blood or marrow transplantation
Graft-versus-host disease prophylaxis
Post-transplantation cyclophosphamide
Post-transplantation lymphoproliferative disorder

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2013.07.013

Cite this

Kanakry, J. A., Kasamon, Y. L., Bolaños-Meade, J., Borrello, I. M., Brodsky, R. A., Fuchs, E. J., Ghosh, N., Gladstone, D. E., Gocke, C. D., Huff, C. A., Kanakry, C. G., Luznik, L., Matsui, W., Mogri, H. J., Swinnen, L. J., Symons, H. J., Jones, R. J., & Ambinder, R. F. (2013). Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biology of Blood and Marrow Transplantation, 19(10), 1514-1517. https://doi.org/10.1016/j.bbmt.2013.07.013

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. / Kanakry, Jennifer A.; Kasamon, Yvette L.; Bolaños-Meade, Javier et al.
In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 10, 10.2013, p. 1514-1517.

Research output: Contribution to journal › Article › peer-review

Kanakry, JA, Kasamon, YL, Bolaños-Meade, J, Borrello, IM, Brodsky, RA , Fuchs, EJ, Ghosh, N, Gladstone, DE, Gocke, CD , Huff, CA, Kanakry, CG, Luznik, L, Matsui, W, Mogri, HJ, Swinnen, LJ , Symons, HJ , Jones, RJ & Ambinder, RF 2013, 'Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis', Biology of Blood and Marrow Transplantation, vol. 19, no. 10, pp. 1514-1517. https://doi.org/10.1016/j.bbmt.2013.07.013

Kanakry JA, Kasamon YL, Bolaños-Meade J, Borrello IM, Brodsky RA , Fuchs EJ et al. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biology of Blood and Marrow Transplantation. 2013 Oct;19(10):1514-1517. doi: 10.1016/j.bbmt.2013.07.013

@article{d4af104f7b404541aaf4ebb818131b76,

title = "Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis",

abstract = "Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.",

keywords = "Allogeneic blood or marrow transplantation, Graft-versus-host disease prophylaxis, Post-transplantation cyclophosphamide, Post-transplantation lymphoproliferative disorder",

author = "Kanakry, {Jennifer A.} and Kasamon, {Yvette L.} and Javier Bola{\~n}os-Meade and Borrello, {Ivan M.} and Brodsky, {Robert A.} and Fuchs, {Ephraim J.} and Nilanjan Ghosh and Gladstone, {Douglas E.} and Gocke, {Christopher D.} and Huff, {Carol Ann} and Kanakry, {Christopher G.} and Leo Luznik and William Matsui and Mogri, {Huzefa J.} and Swinnen, {Lode J.} and Symons, {Heather J.} and Jones, {Richard J.} and Ambinder, {Richard F.}",

note = "Funding Information: Financial disclosure: This work was supported by the National Cancer Institute (grants P01CA15396 , P50CA96888 , P30CA006973 , and T32HL7525 ). The authors have no conflicts of interest to report.",

year = "2013",

month = oct,

doi = "10.1016/j.bbmt.2013.07.013",

language = "English (US)",

volume = "19",

pages = "1514--1517",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis

AU - Kanakry, Jennifer A.

AU - Kasamon, Yvette L.

AU - Bolaños-Meade, Javier

AU - Borrello, Ivan M.

AU - Brodsky, Robert A.

AU - Fuchs, Ephraim J.

AU - Ghosh, Nilanjan

AU - Gladstone, Douglas E.

AU - Gocke, Christopher D.

AU - Huff, Carol Ann

AU - Kanakry, Christopher G.

AU - Luznik, Leo

AU - Matsui, William

AU - Mogri, Huzefa J.

AU - Swinnen, Lode J.

AU - Symons, Heather J.

AU - Jones, Richard J.

AU - Ambinder, Richard F.

N1 - Funding Information: Financial disclosure: This work was supported by the National Cancer Institute (grants P01CA15396 , P50CA96888 , P30CA006973 , and T32HL7525 ). The authors have no conflicts of interest to report.

PY - 2013/10

Y1 - 2013/10

N2 - Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.

AB - Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.

KW - Allogeneic blood or marrow transplantation

KW - Graft-versus-host disease prophylaxis

KW - Post-transplantation cyclophosphamide

KW - Post-transplantation lymphoproliferative disorder

UR - http://www.scopus.com/inward/record.url?scp=84884180614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884180614&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.07.013

DO - 10.1016/j.bbmt.2013.07.013

M3 - Article

C2 - 23871780

AN - SCOPUS:84884180614

SN - 1083-8791

VL - 19

SP - 1514

EP - 1517

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 10

ER -

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this